Hansoh Pharmaceutical (03692) Announces Approval of Dapagliflozin Tablets by China's NMPA

Hansoh Pharma (03692) announced that Jiangsu Hansoh Pharmaceutical Group Co., Ltd., a subsidiary of the company, has obtained the drug registration certificate from the China National Medical Products Administration for its product "Dapagliflozin Tablets".

This product is a sodium-glucose cotransporter (SGLT2) inhibitor, suitable for blood glucose control in adults with type 2 diabetes. The product's receipt of a drug registration certificate will further enrich and improve the group's product portfolio.